EA201390760A1 - Фармацевтическая композиция фосфомицина - Google Patents

Фармацевтическая композиция фосфомицина

Info

Publication number
EA201390760A1
EA201390760A1 EA201390760A EA201390760A EA201390760A1 EA 201390760 A1 EA201390760 A1 EA 201390760A1 EA 201390760 A EA201390760 A EA 201390760A EA 201390760 A EA201390760 A EA 201390760A EA 201390760 A1 EA201390760 A1 EA 201390760A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
phosphomycin
present
fosfomycin
sugar
Prior art date
Application number
EA201390760A
Other languages
English (en)
Other versions
EA023846B1 (ru
Inventor
Карлос Пикорнель Дардер
Original Assignee
Арафарма Груп, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Арафарма Груп, С.А. filed Critical Арафарма Груп, С.А.
Publication of EA201390760A1 publication Critical patent/EA201390760A1/ru
Publication of EA023846B1 publication Critical patent/EA023846B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к твердой фармацевтической композиции фосфомицина, стабильной в отношении окрашивания, подходящей для приема диабетиками и не вызывающая проблем желудочно-кишечного тракта. Фармацевтическая композиция по настоящему изобретению включает фосфомицина трометамол, глицин и, необязательно, другие вспомогательные вещества, такие как сукралоза, диоксид кремния, поливинилпирролидон и ароматизатор; и, по существу, не содержит сахара и сахарных спиртов, таких как сахароза, фруктоза, глюкоза, ксилит, маннит, сорбит или их смеси.
EA201390760A 2010-12-24 2011-12-19 Фармацевтическая композиция фосфомицина EA023846B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201001613A ES2385158B1 (es) 2010-12-24 2010-12-24 Composición farmacéutica de fosfomicina
PCT/ES2011/000366 WO2012085304A1 (es) 2010-12-24 2011-12-19 Composición farmacéutica de fosfomicina

Publications (2)

Publication Number Publication Date
EA201390760A1 true EA201390760A1 (ru) 2013-12-30
EA023846B1 EA023846B1 (ru) 2016-07-29

Family

ID=46313210

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390760A EA023846B1 (ru) 2010-12-24 2011-12-19 Фармацевтическая композиция фосфомицина

Country Status (15)

Country Link
EP (1) EP2656846B1 (ru)
JP (1) JP6012622B2 (ru)
KR (1) KR20140091649A (ru)
CN (1) CN103282038B (ru)
BR (1) BR112013016029A2 (ru)
CA (1) CA2821382C (ru)
DK (1) DK2656846T3 (ru)
EA (1) EA023846B1 (ru)
ES (2) ES2385158B1 (ru)
HK (1) HK1188959A1 (ru)
HU (1) HUE027572T2 (ru)
MX (1) MX342938B (ru)
PL (1) PL2656846T3 (ru)
PT (1) PT2656846T (ru)
WO (1) WO2012085304A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017111718A1 (en) 2015-12-25 2017-06-29 Yusuf Toktamiş Öğün The formulation comprising phosphomycine and ascorbic acid for the treatment of bacterial urinary system infections
CA3147662A1 (en) 2021-02-10 2022-08-10 Labiana Health, S.L. New fosfomycin tablet formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1112282B (it) * 1978-07-19 1986-01-13 Zambon Spa Bis-(2-ammonio-2-idrossimetil-1,3-propandiolo)(2r-cis)-(3-metilossiranil)fosfonato
IT1231013B (it) 1989-07-27 1991-11-08 Zambon Spa Mono (2 ammonio 2 idrossimetil 1,3 propandiolo)(2r,cis) 1,2 epossipropil fosfonato avente migliorate caratteristiche di stabilita' e lavorabilita'.
ES2103682B1 (es) * 1995-09-20 1998-04-01 Lilly Sa Composicion farmaceutica oral de fluoxetina, solida y con caracteristicas organolepticas mejoradas.
ITMI20021725A1 (it) * 2002-08-01 2002-10-31 Zambon Spa Composizioni farmaceutiche ad attivita' antibiotica.
ES2244333B1 (es) * 2004-05-18 2006-08-01 Simbec Iberica, Sl Preparado farmaceutico oral de fosfomicina estable y apto para diabeticos.

Also Published As

Publication number Publication date
CA2821382C (en) 2019-01-08
MX342938B (es) 2016-10-19
EP2656846A4 (en) 2014-07-09
CN103282038A (zh) 2013-09-04
CN103282038B (zh) 2016-08-10
EP2656846B1 (en) 2016-03-30
PL2656846T3 (pl) 2016-09-30
DK2656846T3 (en) 2016-07-04
BR112013016029A2 (pt) 2017-06-13
EP2656846A1 (en) 2013-10-30
KR20140091649A (ko) 2014-07-22
HK1188959A1 (zh) 2014-05-23
EA023846B1 (ru) 2016-07-29
MX2013007232A (es) 2013-08-15
ES2574916T3 (es) 2016-06-23
JP2014500301A (ja) 2014-01-09
JP6012622B2 (ja) 2016-10-25
PT2656846T (pt) 2016-07-08
HUE027572T2 (en) 2016-10-28
CA2821382A1 (en) 2012-06-28
WO2012085304A1 (es) 2012-06-28
ES2385158A1 (es) 2012-07-19
ES2385158B1 (es) 2013-05-28

Similar Documents

Publication Publication Date Title
WO2009115178A3 (de) Gingival-wafer
WO2017075257A3 (en) High intensity sweeteners
NO20081889L (no) Fast vaksine formulering
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
EA201270216A1 (ru) Фармацевтический состав
WO2011124953A3 (en) Controlled release pharmaceutical compositions of tapentadol
CY1115751T1 (el) Φαρμακευτικος συνδυασμος 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλπροπυλ)-φαινολης και ενος αντιεπιληπτικου
GT200600295AA (es) Una formulacion solida de dosificacion farmaceutica (patente fraccionaria derivada de la solicitud de patente no. pi-2006-295)
EA201692443A1 (ru) Водная фармацевтическая композиция тапентадола для перорального введения
UA107174C2 (uk) Кристалічні форми саксагліптину та процес їх одержання (варіанти)
CO6382125A2 (es) Inhibidores de proteína quinasa
PE20121517A1 (es) Compuestos lipopeptidos y metodos relacionados
CL2014001437A1 (es) Compuestos derivados de aril dihidropiridinona y piperidinona como inhibidores de monoacilglicerol aciltransferasa (mgat2); composicion y combinacion farmaceutica; y uso en el tratamiento y prevencion de diabetes, hiperglucemia, retinopatia, sindrome metabolico, entre otras enfermedades.
EA200802444A1 (ru) Стабилизированные фармацевтические композиции, содержащие фезотеродин
EA200801275A1 (ru) Стабилизированные составы карбоната лантана
GT200600347A (es) Nueva formula cristalina iii de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
EA201391651A1 (ru) Сокристаллы l-пролина и лимонной кислоты (2s,3r,4r,5s,6r)-2-(3-((5-(4-фторфенил)тиофен-2-ил)метил)-4-метилфенил)-6-(гидроксиметил)тетрагидро-2h-пиран-3,4,5-триол
NO20092019L (no) Behandling av gjennomtrengende utviklingsforstyrrelser
WO2010139981A3 (en) Processes for preparing crystalline forms of dasatinib
WO2011036521A3 (en) Formulations comprising triptan compounds
EA201300539A1 (ru) Твердая композиция для приема внутрь (варианты), способ терапевтической или нетерапевтической профилактики желудочно-кишечных расстройств или поддержания здорового состояния желудочно-кишечного тракта с ее помощью (варианты) и упаковка, ее содержащая
WO2011006935A3 (en) Tetrazole derivatives
WO2010056527A3 (en) B-biphenyl sulfonamide compounds as ion channel modulators
EA201390760A1 (ru) Фармацевтическая композиция фосфомицина
EA201290229A1 (ru) Производные спиролактама и их применение

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU